List of Excipients in Branded Drug TLANDO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Antares Pharma Inc	TLANDO	testosterone undecanoate	54436-112	AMMONIA	2029-01-08
Antares Pharma Inc	TLANDO	testosterone undecanoate	54436-112	ASCORBYL PALMITATE	2029-01-08
Antares Pharma Inc	TLANDO	testosterone undecanoate	54436-112	FERROSOFERRIC OXIDE	2029-01-08
Antares Pharma Inc	TLANDO	testosterone undecanoate	54436-112	GLYCERIN	2029-01-08

Tlando Excipient Strategy and Commercial Opportunities in Oral Testosterone Replacement

Last updated: August 5, 2026

Tlando is an oral testosterone undecanoate product designed to improve systemic testosterone exposure through a lipid-based absorption strategy. Its commercial opportunity is strongest in differentiated testosterone replacement therapy, where patients and prescribers may prefer oral dosing over injections, gels, patches, or buccal systems. The main excipient priorities are lipid solubilization, intestinal absorption, food-effect control, capsule manufacturability, and global excipient compliance.

What is Tlando and how does its formulation work?

Tlando contains testosterone undecanoate, an esterified form of testosterone administered as an oral capsule. The FDA approved Tlando on June 28, 2022, for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. The product is administered as 225 mg twice daily, for a total daily dose of 450 mg, with food.[1]

Product attribute	Tlando
Active ingredient	Testosterone undecanoate
Dosage form	Oral softgel capsule
Strength	112.5 mg per capsule
Recommended dose	Two capsules twice daily
Total daily dose	450 mg
Administration	With food
FDA application	NDA 214059
Regulatory pathway	505(b)(2)-type development framework
Controlled substance	Testosterone is a Schedule III controlled substance in the United States
Sponsor at approval	Antares Pharma
Current corporate owner	Halozyme Therapeutics, following acquisition of Antares

Testosterone has poor oral bioavailability because of intestinal and hepatic first-pass metabolism. Testosterone undecanoate is highly lipophilic. A lipid-based capsule can improve dissolution in intestinal fluids and promote absorption through intestinal lipid-processing pathways, including transport through the lymphatic system. This approach reduces, but does not eliminate, the pharmacokinetic limitations associated with conventional oral testosterone.

The formulation is commercially important because the active ingredient alone does not create a practical oral product. Excipient selection controls whether testosterone undecanoate remains dispersed, dissolves after dosing, is absorbed consistently, and maintains acceptable exposure across meals and patients.

What excipients are important in the Tlando formulation?

Tlando’s excipient strategy is centered on a lipid vehicle rather than a conventional tablet matrix. Public labeling identifies the product as a softgel capsule and instructs administration with food, which indicates that formulation performance depends on the interaction between the capsule fill, gastrointestinal fluids, and dietary lipids.[1]

Lipid solubilization

Testosterone undecanoate has high lipophilicity and limited aqueous solubility. Suitable oils, fatty acids, surfactants, or co-solvents can:

• Keep the active ingredient dissolved or finely dispersed before administration.
• Improve wetting and dispersion in the gastrointestinal tract.
• Promote formation of colloidal structures during digestion.
• Support intestinal uptake through lipid-associated transport.
• Reduce variability caused by incomplete dissolution.

The most valuable excipient work is likely to involve the balance between solubility and tolerability. A stronger surfactant system may improve dispersion but can create gastrointestinal irritation, capsule-shell compatibility problems, odor, taste, or manufacturing challenges.

Food-dependent absorption

Tlando is labeled for administration with food. That creates both a formulation constraint and a commercial opportunity. A food requirement may improve exposure consistency when patients follow instructions, but it can reduce adherence when patients take doses at irregular times or skip meals.

A next-generation formulation could target:

• Lower food dependence.
• Reduced exposure variability between low-fat and high-fat meals.
• More flexible morning and evening dosing.
• A smaller total daily capsule burden.
• Equivalent exposure at a lower active dose.

The strongest development programs would use in vitro lipolysis, biorelevant dissolution, pharmacokinetic food-effect studies, and population pharmacokinetic modeling to show that the product is less sensitive to meal composition.

Softgel shell and manufacturing excipients

The softgel shell is part of the product’s performance profile. Gelatin, plasticizers, water, colorants, and printing materials influence:

• Shell elasticity and leakage resistance.
• Oxygen and moisture permeability.
• Fill compatibility.
• Stability during shipping.
• Encapsulation speed and yield.
• Storage requirements.

A formulation that uses a non-gelatin shell could expand the addressable market among patients who avoid animal-derived materials. That change would require separate stability, dissolution, and bioequivalence work and could create a new patentable product configuration if the shell and fill system produce a clinically relevant performance benefit.

What commercial opportunities exist for Tlando excipient innovation?

The commercial opportunity is not limited to copying Tlando’s active ingredient. The more defensible opportunities involve improved delivery, adherence, tolerability, and manufacturing.

Opportunity	Product benefit	Commercial value
Lower food effect	More reliable exposure across meals	Better adherence and broader prescribing
Reduced capsule burden	Fewer daily units	Improved convenience
Modified-release delivery	Smoother testosterone exposure	Possible reduction in peak-related adverse effects
Non-gelatin softgel	Broader patient acceptance	Geographic and demographic expansion
Improved oxidative stability	Longer shelf life and fewer impurities	Lower manufacturing and distribution cost
Lower-dose formulation	Reduced API use	Better economics and potentially lower adverse-event burden
Generic-compatible lipid system	Easier development of an ANDA product	Faster commercial entry if exclusivity permits
Combination therapy	Testosterone plus selected supportive therapy	Differentiation, subject to clinical and regulatory requirements

Reduced pill burden

Tlando requires four 112.5 mg capsules per day. A formulation containing a higher drug load or improved absorption could reduce administration to one or two capsules daily. The main technical barrier is the large dose of testosterone undecanoate required to achieve therapeutic testosterone exposure.

A high-load softgel may increase fill viscosity, shell stress, leakage risk, and batch-to-batch variability. A hard capsule with a lipid liquid fill, self-emulsifying system, or lipid multiparticulate may offer an alternative, but changes to the dosage form would require substantial comparative pharmacokinetic and stability data.

Food-independent oral testosterone

Food independence is the clearest formulation white space. A product that achieves comparable exposure under fasting and fed conditions could compete on convenience against Tlando and other oral testosterone products.

Potential approaches include:

• Self-emulsifying drug-delivery systems.
• Solid lipid or nanostructured lipid carriers.
• Supersaturating lipid systems.
• Absorption-enhancing excipients.
• Amorphous solid dispersions.
• Enteric or delayed-release systems that target intestinal absorption.
• Prodrug or ester optimization.

The risk is that absorption enhancers can introduce gastrointestinal safety concerns and may increase exposure unpredictably. Any product claiming reduced food dependence would need controlled fed and fasted studies and careful assessment of testosterone and dihydrotestosterone exposure.

How does Tlando compare with competing testosterone products?

Tlando competes with several dosage forms rather than with one direct product.

Product category	Examples	Main advantage	Main limitation relative to Tlando
Oral testosterone undecanoate	Tlando, Jatenzo, Kyzatrex	Avoids injections and topical application	Food, dose, blood-pressure, and monitoring issues
Intramuscular injection	Testosterone cypionate, enanthate	Low acquisition cost and established use	Needles, clinic visits, peak-trough exposure
Topical gel	AndroGel and generics	Flexible dosing and broad experience	Transfer risk, daily skin application
Transdermal patch	Testosterone patches	Noninvasive systemic delivery	Skin reactions and lower convenience
Buccal system	Striant-type products	Avoids injections	Oral irritation and administration complexity
Implant	Testosterone pellets	Long dosing interval	Invasive insertion and difficult dose adjustment

Tlando’s commercial positioning depends on its ability to convert patients who reject injections or topical products. Its principal disadvantages are the four-capsule daily regimen, food requirement, monitoring burden, and potential class-related cardiovascular and prostate risks.

When does Tlando lose regulatory exclusivity?

Tlando received FDA approval in 2022. Because testosterone is an established active ingredient, the product does not rely on new chemical entity exclusivity. Its regulatory protection is more likely to derive from clinical investigation exclusivity, listed patents, formulation claims, and litigation outcomes.

Protection type	Relevance to Tlando
New chemical entity exclusivity	Unlikely because testosterone and testosterone undecanoate were previously known
Three-year clinical investigation exclusivity	Potentially relevant to the approved formulation and indication
Orphan-drug exclusivity	Not indicated for the general male hypogonadism indication
Pediatric exclusivity	Depends on a qualifying FDA pediatric determination
Patent protection	May cover lipid formulations, oral testosterone delivery, dosing, or manufacturing
Regulatory exclusivity end date	Must be confirmed from current FDA Orange Book and FDA exclusivity records

The three-year exclusivity period associated with a 2022 approval would generally have been relevant through approximately June 2025 if granted and if applicable to the product’s submission. That period would not block all generic development. It could restrict approval of an abbreviated application relying on the protected clinical investigations for the same conditions of approval.

What patents protect Tlando?

Tlando’s likely patent value lies in formulation and delivery claims rather than in the testosterone molecule itself. Relevant claim categories may include:

• Oral testosterone undecanoate compositions.
• Lipid vehicles and solubilizing systems.
• Softgel dosage forms.
• Testosterone exposure profiles.
• Dosing regimens that achieve therapeutic serum testosterone.
• Methods for treating testosterone deficiency.
• Manufacturing processes for filling and sealing the capsule.
• Stability and impurity-control methods.

Patent analysis should distinguish between broad composition claims and narrower claims that require specific excipient ratios, capsule materials, or pharmacokinetic limitations. A formulation patent with a narrow excipient window may be easier to design around than a claim covering a broad class of lipid systems.

The Orange Book is the controlling source for patents listed against the approved NDA. Any commercial entrant should review the current Orange Book listing, FDA patent certification requirements, USPTO prosecution history, and relevant district-court or Federal Circuit records before relying on an expiration date.

Are Paragraph IV challenges likely for Tlando?

Paragraph IV risk is material because testosterone undecanoate is a known active ingredient and oral testosterone products can be developed through an abbreviated pathway if the reference-product requirements are satisfied.

A generic applicant could challenge patents by asserting that:

• The claims are invalid for anticipation or obviousness.
• The claims are not infringed by the proposed formulation.
• The listed patent does not claim the approved product or method of use.
• The patent claims an excipient combination that the applicant has designed around.
• The listed method-of-use patent is not relevant to the proposed label.

The principal technical barrier is not API synthesis. It is demonstrating bioequivalence for a lipid formulation whose exposure may vary with food composition, meal timing, endogenous testosterone levels, and active-metabolite formation.

A Paragraph IV filing could trigger a 30-month stay if the NDA holder timely files an infringement action. Commercial launch would then depend on litigation timing, settlement terms, patent outcomes, and any exclusivity remaining at the time of approval.

What formulation patents could create new commercial protection?

A reformulated oral testosterone product could seek protection around measurable product attributes rather than a generic description of testosterone delivery.

Potentially valuable claim strategies include:

Food-effect claims

Claims could focus on a defined ratio of fed-to-fasted exposure, provided the result is supported by clinical data. These claims are commercially useful because food dependence is a recognized limitation of oral testosterone products.

Excipient-ratio claims

A formulation could claim defined ranges of oil, surfactant, co-solvent, and testosterone undecanoate. Narrow numerical ranges can provide protection when the formulation’s performance changes sharply outside the claimed window.

Pharmacokinetic claims

Claims may target peak testosterone concentration, exposure over a dosing interval, time to peak concentration, or reduced peak-to-trough fluctuation. These claims require robust clinical support and can be difficult to enforce if the generic product has a different exposure profile.

Manufacturing claims

Control of oxygen exposure, fill homogeneity, capsule sealing, degradation products, and storage conditions can create manufacturing barriers. These claims are most valuable when they reduce impurity formation or maintain dissolution performance over the labeled shelf life.

How strong is the Tlando patent estate?

The estate is potentially stronger against direct formulation copies than against technically distinct oral testosterone products. Its strength depends on four factors:

1. The breadth and remaining term of listed formulation claims.
2. Whether claims require specific excipients or pharmacokinetic results.
3. The availability of noninfringing lipid systems.
4. The quality of comparative clinical and analytical evidence supporting the claims.

The active ingredient provides limited exclusivity because testosterone undecanoate is established. The commercial moat therefore depends on formulation know-how, regulatory complexity, prescriber familiarity, manufacturing scale, and brand access.

What licensing and ownership transactions affect Tlando?

Tlando originated from Lipocine’s oral testosterone technology and was commercialized in the United States through Antares Pharma. Halozyme acquired Antares in 2022, bringing Antares’ commercial assets and related rights into Halozyme’s portfolio.[2]

The ownership history matters for diligence because patent assignments, license rights, royalty obligations, prosecution control, and enforcement rights may be split between the originating technology company and the commercial partner. A transaction review should examine:

• U.S. and international territory rights.
• Royalty and milestone obligations.
• Patent prosecution and enforcement control.
• Rights to improvements and follow-on formulations.
• Change-of-control provisions.
• Rights to sublicense or transfer the product.
• Allocation of litigation costs and recoveries.

What manufacturing and geographic barriers apply?

Tlando’s manufacturing barriers are higher than those of a standard immediate-release tablet. A commercial-scale producer must control:

• Testosterone undecanoate dispersion and fill uniformity.
• Softgel encapsulation parameters.
• Shell moisture and oxygen exposure.
• Leakage and brittleness.
• Lipid oxidation.
• Dissolution after storage.
• Impurity and degradation-product limits.
• Serialization and controlled-substance handling.

Geographic expansion also requires country-specific review of excipient acceptability, gelatin sourcing, colorants, food-effect labeling, controlled-substance rules, and local patent rights. A U.S. formulation may require modification for Europe, Japan, or emerging markets if an excipient is restricted or if the approved dosing instructions differ.

What generic launch scenarios exist for Tlando?

Three launch scenarios are commercially plausible:

Scenario	Trigger	Market impact
Early authorized or negotiated entry	Settlement or noninfringing product	Gradual price erosion with controlled launch timing
Litigation-delayed entry	Paragraph IV suit and 30-month stay	Brand retains share while litigation proceeds
Post-patent generic entry	Patent expiry without enforceable barriers	Rapid price pressure and payer substitution

The initial generic threat is likely to focus on an oral testosterone undecanoate capsule with a comparable lipid system. A second wave could involve alternative softgel or liquid-filled hard-capsule technologies that avoid specific formulation claims while pursuing comparable exposure.

Key Takeaways

• Tlando’s primary differentiation is oral delivery of testosterone undecanoate through a lipid-based softgel formulation.
• The product’s major formulation constraint is administration with food.
• The strongest excipient opportunity is a food-independent or food-flexible formulation.
• Reduced capsule burden is commercially attractive but technically difficult because of the high daily testosterone undecanoate dose.
• Patent value is likely concentrated in formulation, dosing, pharmacokinetic, and manufacturing claims rather than the testosterone molecule.
• Paragraph IV risk is credible because the active ingredient is established and generic applicants can pursue formulation workarounds.
• Tlando has no biosimilar risk because it is a small-molecule drug, not a biologic.
• Halozyme’s acquisition of Antares is relevant to licensing, patent enforcement, and commercial ownership analysis.
• Manufacturing know-how, softgel performance, impurity control, and food-effect management may preserve commercial value after regulatory exclusivity expires.

FAQs About Tlando Excipients and Commercial Strategy

Can Tlando be reformulated as a tablet?

Yes, but a tablet would need to overcome testosterone undecanoate’s poor aqueous solubility and first-pass metabolism. A lipid tablet, self-emulsifying system, amorphous dispersion, or absorption-enhanced formulation could be evaluated, but it would require comparative pharmacokinetic and stability data.

Is Tlando a biologic subject to biosimilar competition?

No. Tlando contains testosterone undecanoate, a small-molecule active ingredient. Competitors would generally pursue generic-drug or 505(b)(2) pathways rather than the biosimilar pathway.

Which excipient creates the largest commercial differentiation opportunity?

The most valuable excipient system is one that improves lipid digestion and intestinal absorption while reducing dependence on meal composition. The commercial claim must be supported by controlled fed and fasted pharmacokinetic data.

Does Tlando’s food requirement create an adherence risk?

Yes. Twice-daily administration with food can create missed-dose and inconsistent-meal risks. A formulation with lower food sensitivity could compete directly on convenience and adherence.

What is the most important diligence document for Tlando patent risk?

The current FDA Orange Book listing for NDA 214059, together with the corresponding patent texts, USPTO prosecution histories, and any Paragraph IV litigation records, provides the core patent-risk record.[3]

References

1. U.S. Food and Drug Administration. (2022). Tlando (testosterone undecanoate) capsules, prescribing information. FDA. https://www.accessdata.fda.gov
2. Halozyme Therapeutics, Inc. (2022). Halozyme completes acquisition of Antares Pharma. https://ir.halozyme.com
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm